NO20024134D0 - 1,5-disubstituerte 3,4-dihydro-1H-pyrimido[4,5-D]-pyrimidin-3- onforbindelser og deres anvendelse ved behandling av CSBP/P38kinaseformidlede sykdommer - Google Patents

1,5-disubstituerte 3,4-dihydro-1H-pyrimido[4,5-D]-pyrimidin-3- onforbindelser og deres anvendelse ved behandling av CSBP/P38kinaseformidlede sykdommer

Info

Publication number
NO20024134D0
NO20024134D0 NO20024134A NO20024134A NO20024134D0 NO 20024134 D0 NO20024134 D0 NO 20024134D0 NO 20024134 A NO20024134 A NO 20024134A NO 20024134 A NO20024134 A NO 20024134A NO 20024134 D0 NO20024134 D0 NO 20024134D0
Authority
NO
Norway
Prior art keywords
csbp
pyrimido
pyrimidin
disubstituted
dihydro
Prior art date
Application number
NO20024134A
Other languages
English (en)
Other versions
NO20024134L (no
NO326409B1 (no
Inventor
Jerry L Adams
Jeffrey Charles Boehm
Ralph Floyd Hall
John J Taggart
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20024134D0 publication Critical patent/NO20024134D0/no
Publication of NO20024134L publication Critical patent/NO20024134L/no
Publication of NO326409B1 publication Critical patent/NO326409B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
NO20024134A 2000-03-02 2002-08-30 1,5-disubstituerte 3,4-dihydro-1H-pyrimido[4,5-D]-pyrimidin-2-onforbindelser og deres anvendelse samt farmasoytisk preparat inneholdende en slik forbindelse NO326409B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18641900P 2000-03-02 2000-03-02
PCT/US2001/006688 WO2001064679A1 (en) 2000-03-02 2001-03-02 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases

Publications (3)

Publication Number Publication Date
NO20024134D0 true NO20024134D0 (no) 2002-08-30
NO20024134L NO20024134L (no) 2002-10-24
NO326409B1 NO326409B1 (no) 2008-12-01

Family

ID=22684876

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024134A NO326409B1 (no) 2000-03-02 2002-08-30 1,5-disubstituerte 3,4-dihydro-1H-pyrimido[4,5-D]-pyrimidin-2-onforbindelser og deres anvendelse samt farmasoytisk preparat inneholdende en slik forbindelse

Country Status (26)

Country Link
EP (1) EP1265900B1 (no)
JP (1) JP2003525295A (no)
KR (1) KR100806978B1 (no)
CN (1) CN100482664C (no)
AR (2) AR030053A1 (no)
AT (1) ATE362473T1 (no)
AU (2) AU3999201A (no)
BR (1) BR0108715A (no)
CA (1) CA2402092C (no)
CY (1) CY1106816T1 (no)
CZ (1) CZ20022933A3 (no)
DE (1) DE60128457T2 (no)
DK (1) DK1265900T3 (no)
ES (1) ES2287107T3 (no)
HK (1) HK1052932A1 (no)
HU (1) HUP0204431A3 (no)
IL (3) IL151426A0 (no)
MX (1) MXPA02008588A (no)
MY (1) MY141144A (no)
NO (1) NO326409B1 (no)
NZ (1) NZ520914A (no)
PL (1) PL358280A1 (no)
PT (1) PT1265900E (no)
TW (1) TWI290926B (no)
WO (1) WO2001064679A1 (no)
ZA (1) ZA200207017B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69939168D1 (de) 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung
JP4524072B2 (ja) * 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
CA2431904A1 (en) * 2000-12-20 2002-08-01 Merck & Co., Inc. (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
GB0124848D0 (en) 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
NZ533865A (en) 2002-02-12 2006-02-24 Smithkline Beecham Corp Nicotinamide derivates useful as p38 inhibitors
CA2474578C (en) 2002-02-13 2009-08-25 F. Hoffmann-La Roche Ag Novel pyridin- and pyrimidin-derivatives
AU2003225072A1 (en) * 2002-04-19 2003-11-03 Smithkline Beecham Corporation Novel compounds
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
GB0218800D0 (en) * 2002-08-13 2002-09-18 Celltech R&D Ltd Chemical compounds
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
EP1539121A4 (en) 2002-08-29 2008-08-13 Scios Inc METHOD OF REQUESTING OSTEOGENESIS
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
WO2004043367A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
MXPA05010765A (es) 2003-04-10 2005-12-12 Hoffmann La Roche Compuestos pirimido.
WO2005030091A2 (en) 2003-09-25 2005-04-07 Scios Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
PT1699800E (pt) * 2003-12-23 2010-04-12 Novartis Ag Inibidores de quinase p-38 heterocíclicos bicíclicos
CA2590294A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
JP5201817B2 (ja) * 2005-10-28 2013-06-05 大塚製薬株式会社 医薬組成物
US20090318424A1 (en) * 2006-06-16 2009-12-24 Mauro Corsi Novel compounds
US20100069409A1 (en) * 2006-06-16 2010-03-18 Glaxo Group Limited "novel compounds"
KR101040394B1 (ko) * 2010-05-18 2011-06-09 (주)이성산업 역화 방지 기능을 갖는 야외용 가스 히터
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
ES2892423T3 (es) 2013-03-15 2022-02-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
BR112015022191A8 (pt) 2013-03-15 2018-01-23 Celgene Avilomics Res Inc compostos heteroarila e usos dos mesmos
AU2014336775B2 (en) 2013-10-16 2018-04-05 Shanghai Yingli Pharmaceutical Co., Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
TW202327600A (zh) 2021-10-20 2023-07-16 香港商英科智能有限公司 甲硫胺酸腺苷轉移酶２ａ（ｍａｔ２ａ）抑制劑及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60226882A (ja) * 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
CN1093130C (zh) * 1996-08-06 2002-10-23 辉瑞大药厂 被取代的吡啶并6,6－二环衍生物
DE69939168D1 (de) * 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung
JP2002517486A (ja) * 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
ES2228123T3 (es) * 1998-10-23 2005-04-01 F. Hoffmann-La Roche Ag Heterociclos de nitrogeno biciclicos.

Also Published As

Publication number Publication date
ZA200207017B (en) 2004-02-26
PL358280A1 (en) 2004-08-09
CZ20022933A3 (cs) 2003-02-12
ES2287107T3 (es) 2007-12-16
WO2001064679A1 (en) 2001-09-07
NO20024134L (no) 2002-10-24
AU2001239992B2 (en) 2005-09-01
KR20020082858A (ko) 2002-10-31
CA2402092A1 (en) 2001-09-07
JP2003525295A (ja) 2003-08-26
DE60128457D1 (de) 2007-06-28
HUP0204431A3 (en) 2006-01-30
CN100482664C (zh) 2009-04-29
IL151426A (en) 2011-01-31
AR040075A2 (es) 2005-03-16
CY1106816T1 (el) 2012-01-25
MY141144A (en) 2010-03-15
HK1052932A1 (en) 2003-10-03
DK1265900T3 (da) 2007-09-24
ATE362473T1 (de) 2007-06-15
AU3999201A (en) 2001-09-12
HUP0204431A1 (hu) 2003-04-28
IL189865A0 (en) 2008-08-07
CN1422273A (zh) 2003-06-04
EP1265900B1 (en) 2007-05-16
NO326409B1 (no) 2008-12-01
IL151426A0 (en) 2003-04-10
PT1265900E (pt) 2007-08-22
TWI290926B (en) 2007-12-11
EP1265900A4 (en) 2004-11-10
AR030053A1 (es) 2003-08-13
KR100806978B1 (ko) 2008-02-25
BR0108715A (pt) 2004-04-27
NZ520914A (en) 2004-03-26
DE60128457T2 (de) 2008-01-17
CA2402092C (en) 2012-01-24
EP1265900A1 (en) 2002-12-18
MXPA02008588A (es) 2003-02-24

Similar Documents

Publication Publication Date Title
NO20024134L (no) 1,5-disubstituerte 3,4-dihydro-1H-pyrimido[4,5-D]-pyrimidin-2- onforbindelser og deres anvendelse ved behandling av CSBP/P38kinaseformidlede sykdommer
NO20032695D0 (no) Karboksamidderivater og deres anvendelse ved behandling av tromboemboliskesykdommer
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
NO20034169D0 (no) MCH-antagonister og deres anvendelse ved behandling av fedme
NO20024742D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
NO20022680L (no) Farmasoytiske kombinasjoner og deres anvendelse ved behandling av gastrointestinale forstyrrelser
NO20041588L (no) Anvendelse av flibanserin ved behandling av seksuelle forstyrrelser
PL362984A1 (en) Compounds useful in the treatment of inflammatory diseases
NO20052699D0 (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
DE60137929D1 (de) Verwendung von lanthan bei der behandlung von knochenerkrankungen
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
DE60203197D1 (de) 4-(oxadiazol-3-yl)-1,4-diazabizyklo[3.2.2]-nonanderivate, ihre herstellung und therapeutische verwendung
DE60103394D1 (de) 4-(2-phenylthiazol-5-yl)1,4-diazabicyclo[3.2.2]nonanederivate, ihre herstellung und therapeutische verwendung
NO20033498D0 (no) Fremgangsmåte for behandling og törking av trevirke
GB0003254D0 (en) Heterocyclic compounds and their therapeutic use
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
NO20033434D0 (no) 3,7-diazabicyklo(3.3.0)oktaner og anvendelse derav ved behandling av hjertearrytmier
NO20023448D0 (no) Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
DK1345598T3 (da) Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser
NO20040659L (no) Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom
NO20023803L (no) Anvendelse av mirtazapin for behandling av sövnforstyrrelser
NO20043029L (no) Karboksamidinderivater og deres anvendelse ved behandling av vaskulaere sykdommer
NO20024746L (no) Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom
NO20033541D0 (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees